Table 2.
Stratification of patients according to clinical characteristics of COVID-19 symptoms.
| Parameter | Total (n = 74) | Males (n = 47) | Females (n = 27) |
|---|---|---|---|
| SARS severity | |||
| ——Mild | 14 (18.92%) | 4 (8.51%) | 10 (37.04%) |
| ——Severe | 33 (44.59%) | 24 (51.06%) | 9 (33.33%) |
| ——Critical | 11 (14.86%) | 7 (14.89%) | 4 (14.81%) |
| ——Fatal | 16 (21.62%) | 12 (25.53%) | 4 (14.81%) |
| Ventilation | |||
| ——None | 14 (18.92%) | 4 (8.51%) | 10 (37.04%) |
| ——Nasal | 18 (24.32%) | 11 (23.40%) | 7 (25.93%) |
| 11 (14.86%) | 8 (17.02%) | 3 (11.11%) | |
| ——Noninvasive vent | 11 (14.86%) | 9 (19.15%) | 2 (7.41%) |
| 15 (20.27%) | 11 (23.40%) | 4 (14.81%) | |
| 5 (6.76%) | 4 (8.51%) | 1 (3.70%) | |
| Use of corticosteroids | 62 (83.78%) | 45 (95.74%) | 17 (62.96%) |
| Concomitant bacterial infections | 28 (37.84%) | 20 (42.55%) | 8 (29.63%) |
| Kidney failure | 14 (18.92%) | 11 (23.40%) | 3 (11.11%) |
| Sepsis | 5 (6.76%) | 5 (10.64%) | 0 |
| Pancreatitis | 1 (1.35%) | 1 (2.13%) | 0 |
| Coagulation failure | 6 (8.11%) | 4 (8.51%) | 2 (7.41%) |
| Cardiac failure | 6 (8.11%) | 4 (8.51%) | 2 (7.41%) |
| Liver failure | 4 (5.41%) | 4 (8.51%) | 0 |
| Other general symptoms | 9 (12.16%) | 7 (14.89%) | 2 (7.41%) |
| Hematological disorders | 16 (21.62%) | 9 (19.15%) | 7 (25.93%) |
| Diabetes | 27 (36.49%) | 18 (38.30%) | 9 (33.33%) |
| Cancer | 13 (17.57%) | 7 (14.89%) | 6 (22.22%) |
| Hypertension | 43 (58.11%) | 32 (68.09%) | 11 (40.74%) |
| Obesity | 49 (66.22%) | 33 (70.21%) | 16 (59.26%) |
| Chronic lung disease | 34 (45.95%) | 18 (38.3%) | 16 (59.26%) |